U87 CAR-T
Phase 1Cell therapy
U87 CAR-T is one of 4 small molecule programs targeting Head and Neck Tumors. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Head and Neck Tumors
#DrugCompanyPhaseTrials
1Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 2
Si-B036
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 1
GT201
GGrit Biotechnology
Preclinical
U87 CAR-T
SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumor1 trial
U87 CART in Treatment of Advanced Solid Tumor
Unknown status·SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd·Phase 1·NCT05605197·12 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for U87 CAR-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details